StockData

AC Immune vs Aclaris Therapeutics

ACIU and ACRS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ACIU and ACRS compare

Aclaris Therapeutics grew revenue faster over the last twelve months (−51.0% versus −86.9% for AC Immune).

Aclaris Therapeutics scores higher on the StockData Score (5 against 3 for AC Immune), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricACIUACRS
Size and price
Market cap–$531M
Share price$2.09$3.60
Change, 1 year−35.3%55.4%
Change, 5 years−59.6%−71.4%
Beta (5Y)0.220.96
Employees12273
StockData Score
Total score35 (better)
Valuation score00
Growth score00
Performance score00
Health score35 (better)
Dividend score00
Valuation
P/S–64.6×
P/B–4.3×
FCF yield–−11.7%
Fair value–$1.42
Margin of safety–−155%
Growth
Revenue growth (TTM)−86.9%−51.0% (better)
Revenue growth, 5Y average−25.4%3.8% (better)
Profitability
Gross margin–79.5%
Operating margin−1940%−1050% (better)
Net margin–−921%
FCF margin−1964%−757% (better)
Return on equity–−59.1%
Financial health
Debt / equity–0.00
Interest coverage−362.9×–
Current ratio0.933.46 (better)
Altman Z-score–−3.16
Piotroski F-score–3
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions–82.3%
Held by insiders4.4%13.3%
Insider net buying, 12 months−$27.9K (better)−$1.4M
Short interest, % of float–9.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.